Keywords: vical, initiates, ph, iii, trial, allovectin-7, usa-based
Vical initiates Ph III trial of Allovectin-7
Article | 22 January 2007
USA-based Vical has initiated a Phase III pivotal trial of its cancer immunotherapeutic Allovectin-7 as first-line therapy in chemotherapy-naive patients ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
